Summary of COVID-19 tiprelestat studies

1. Bergs et al., Tiprelestat for treatment of hospitalized COVID-19: results of the double-blind randomized placebo-controlled COMCOVID trial

17 patient tiprelestat late treatment RCT: 189% higher mortality (p=1), 11% lower progression (p=1), 22% shorter ICU admission (p=0.85), and 40% lower need for oxygen therapy (p=0.52).
RCT 17 hospitalized COVID-19 patients showing no significant differences with tiprelestat (recombinant human elafin, a neutrophil elastase inhibitor). There was a trend toward benefit for oxygen support.
Sep 2025, Advances in Therapy, https://link.springer.com/10.1007/s12325-025-03362-w, https://c19p.org/bergs